Propolis associated with Royal JellyRoyal JellyPlacebo
Propolis associated with Royal Jelly: The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis together, for 2 months.
Royal Jelly: The participants will consume 1 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
Placebo: The participant will consume 4 capsules a day of placebo, for 2 months.
Study summary
This work aims to evaluate the effects of the association of green propolis extract with royal jelly on inflammation and oxidative stress in participants with chronic kidney diseases (CKD) and Systemic arterial hypertension (SAH), in a longitudinal, randomized, double-blind, placebo-controlled clinical trial that will be carried out for 2 months.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* patients in stages 3 and 5 of CKD (GFR from 15 to 59 mL/min),
* patients receiving ambulatorial nutrition treatment at least 6 months
* patients on regular Hemodialysis treatment for at least 6 months
* patients using one to three antihypertensive drugs
Exclusion Criteria:
* autoimmune and infectious diseases,
* diabetes
* cancer
* AIDS
* pregnant women
* patients using catabolic drugs or antibiotics;
* patients with catheter access to hemodialysis;
* patients using antioxidant vitamin supplements, prebiotics, probiotics, symbiotic,
* Patients on regular intake of propolis who are allergic to corn starch or report being allergic to bee stings.
* patients with acute myocardial infarction (AMI) and/or cerebrovascular accident (CVA)
Primary outcome measure(s)
Change in factor nuclear kappaB — Baseline and 8 weeks (2 months) Get blood samples to evaluate the supplementation effects in factor nuclear kappaB by quantitative real-time polymerase chain reaction.
Change in intestinal microbiota — Baseline and 8 weeks (2 months) Stool samples will be collected to evaluate the taxa of bacteria colonizing the intestinal microbiota through short-read sequencing of the V4 region of the RNA ribosomal (rRNA) gene on the Illumina platform.
Trial sites (2)
Facility
City
Region
Status
Denise Mafra
Rio de Janeiro
Rio de Janeiro
Recruiting
Denise Mafra
Rio de Janeiro
Rio de Janeiro
Recruiting
More Universidade Federal Fluminense trials in Brazil
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
